Ascendis Pharma A/S (ASND) Receives $31.50 Consensus PT from Analysts

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have been given a consensus recommendation of “Hold” by the eight research firms that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $31.50.

A number of equities analysts have recently weighed in on the company. Leerink Swann reaffirmed a “hold” rating and set a $28.00 target price on shares of Ascendis Pharma A/S in a research report on Friday, September 1st. Zacks Investment Research lowered Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research report on Wednesday, August 23rd. BidaskClub lowered Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research report on Wednesday, August 9th. Credit Suisse Group set a $28.00 target price on Ascendis Pharma A/S and gave the stock a “buy” rating in a research report on Tuesday, July 18th. Finally, TheStreet lowered Ascendis Pharma A/S from a “c-” rating to a “d” rating in a research report on Thursday, June 15th.

COPYRIGHT VIOLATION WARNING: This piece was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://ledgergazette.com/2017/09/16/ascendis-pharma-as-asnd-receives-31-50-consensus-pt-from-analysts.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE grew its stake in Ascendis Pharma A/S by 23.6% in the 1st quarter. Bank of America Corp DE now owns 5,345 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 1,020 shares during the period. Alps Advisors Inc. grew its stake in Ascendis Pharma A/S by 7.9% in the 2nd quarter. Alps Advisors Inc. now owns 29,264 shares of the biotechnology company’s stock valued at $812,000 after purchasing an additional 2,144 shares during the period. Bank of Montreal Can grew its stake in Ascendis Pharma A/S by 127.4% in the 2nd quarter. Bank of Montreal Can now owns 4,535 shares of the biotechnology company’s stock valued at $126,000 after purchasing an additional 2,541 shares during the period. Victory Capital Management Inc. bought a new position in Ascendis Pharma A/S in the 1st quarter valued at $144,000. Finally, Karp Capital Management Corp bought a new position in Ascendis Pharma A/S in the 1st quarter valued at $203,000. 71.60% of the stock is owned by institutional investors and hedge funds.

Shares of Ascendis Pharma A/S (NASDAQ ASND) traded up 1.09% during trading on Wednesday, hitting $29.55. 189,029 shares of the stock traded hands. The company has a 50-day moving average of $29.05 and a 200-day moving average of $29.34. The firm’s market cap is $960.43 million. Ascendis Pharma A/S has a 52 week low of $17.15 and a 52 week high of $30.57.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Friday, August 18th. The biotechnology company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.24). Ascendis Pharma A/S had a negative return on equity of 67.76% and a negative net margin of 2,977.70%. The firm had revenue of $0.44 million for the quarter, compared to analyst estimates of $0.78 million. During the same period in the previous year, the company earned ($0.53) earnings per share. Ascendis Pharma A/S’s revenue for the quarter was down 61.4% compared to the same quarter last year. On average, analysts forecast that Ascendis Pharma A/S will post ($0.17) EPS for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply